Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesVascular/Cardiothoracic Surgeryevicore Cerebrovascular Endovascular Prior Auth | …
    Ask Trek AI about this page
    CurrentevicorePolicy CVI.100.A

    Cerebrovascular Intervention (Endovascular Embolization and Stents)

    Customize your policy alerts

    Sign up for evicore Policy CVI.100.A alerts

    Get alerted when Policy CVI.100.A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior-authorization guidance for cerebrovascular endovascular procedures (embolization, angioplasty, stents, flow diverters) for members covered under Cigna plans administered with EviCore review. It affects providers requesting authorization for cerebrovascular endovascular interventions.

    Policy Summary
    Payerevicore
    PolicyCerebrovascular Intervention (Endovascular Embolization and Stents)
    Policy CodePolicy CVI.100.A
    Change TypeNo material changes
    Effective DateNov 5, 2026
    Next Review Date
    Key ActionSubmit prior-authorization at least two weeks before elective procedures with required clinical history, recent imaging, and documentation of conservative therapy or prior interventions as applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Procedures listed
    ≥5 mmAneurysm size threshold
    ≥8 mmcSDH threshold
    >25 cm H2OIIH LP pressure

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >50%Stenosis requirement
    2026Document year

    Coverage Criteria for Cerebrovascular Endovascular Procedures

    inv-01: Endovascular Treatment of Intracerebral Pathology — Medically Necessary Indications

    Endovascular treatment of intracerebral pathology is considered medically necessary when recent clinical history documents any of the following:

    Medically necessary indications: Arteriovenous malformations (any size); Ruptured aneurysm with subarachnoid hemorrhage (SAH); Symptomatic aneurysm (including visual changes or protracted headache) without SAH; "Blister aneurysm" of the supraclinoid segment of the internal carotid artery; Asymptomatic saccular aneurysm meeting size or morphologic criteria (≥5 mm OR ≥3 mm with dysmorphic features or documented growth on follow-up imaging); Persistent or recurrent aneurysm filling after prior intervention; Highly vascular tumors as primary treatment or prior to surgical resection.

    inv-02: Endovascular treatment of intracerebral pathology — medically necessary criteria

    Considered medically necessary when recent clinical history documents any of the following:

    Indications list: Arteriovenous malformations (any size); Ruptured aneurysm with SAH; Symptomatic aneurysm (visual changes or protracted headache) without SAH; Blister aneurysm of the supraclinoid ICA; Asymptomatic saccular aneurysm ≥5 mm OR ≥3 mm with dysmorphic features or evidence of growth on follow-up imaging; Persistent or recurrent aneurysm filling after prior intervention; Highly vascular tumors as primary therapy or prior to surgical resection.

    inv-03: Middle meningeal artery embolization (MMAE) — medically necessary criteria

    MMAE is considered medically necessary for any of the following clinical scenarios:

    MMAE indications: Asymptomatic chronic subdural hematoma measuring ≥8 mm on imaging; Symptomatic chronic subdural hematoma as an adjunct to surgical decompression; Chronic subdural hematoma in the setting of coagulopathy or while on antiplatelet therapy and/or unable to undergo surgical drainage; Prophylactic embolization after surgical evacuation (even without postoperative recurrence).

    inv-04: Endovascular intervention for intracranial venous stenosis — IIH criteria

    For idiopathic intracranial hypertension (all of the following must be present):

    IIH venous stenting criteria: Papilledema on ocular exam; Elevated intracranial pressure on lumbar puncture (>25 cm H2O); Failed medical therapy including lifestyle changes, diuretics, and acetazolamide; Venous sinus stenosis documented by >50% stenosis on MRV/CTV/venography OR a significant trans-stenotic pressure gradient (>8 mmHg) during diagnostic catheter venogram; Ability to tolerate dual antiplatelet therapy (aspirin and clopidogrel) for 1 month.

    inv-05: Venous stenting for pulsatile tinnitus — criteria

    Considered medically necessary when ALL of the following are present:

    Pulsatile tinnitus venous stenting: Failed medical therapy including lifestyle changes, diuretics, and acetazolamide; Venous sinus stenosis documented by >50% stenosis on MRV/CTV/venography OR a pressure gradient >4 mmHg during diagnostic catheter venogram; Ability to tolerate dual antiplatelet therapy (aspirin and clopidogrel) for 1 month.

    inv-06: Intervention for recurrent intracranial venous stenosis after prior treatment

    Recurrent stenosis: Considered medically necessary for recurrent intracranial venous stenosis after prior treatment when any of the following are present: evidence of ≥30% stenosis on MRV, CTV, or angiogram OR a trans-stenotic gradient >8 mmHg during invasive angiography.

    Prophylactic percutaneous transluminal angioplasty of intracranial arteries after aneurysmal subarachnoid hemorrhage is not covered unless there is a concurrent diagnosis of both subarachnoid hemorrhage and ischemia. This limitation applies to intracranial balloon angioplasty and intracranial stent placement when performed prophylactically in the post-aneurysmal subarachnoid hemorrhage setting.

    Endovascular treatment for intracranial atherosclerosis is explicitly stated as not considered medically necessary. Additionally, endovascular interventions proposed for non-specific indications such as headache (without other supporting clinical or imaging findings) are stated as not medically necessary.

    The reference-list excerpts provided do not include additional explicit coverage exclusions beyond those stated elsewhere in the policy text; the citation list is limited to supporting literature and does not itself define exclusions.

    Endovascular intervention for intracranial venous stenosis is addressed with specific, condition‑based criteria (e.g., for IIH and for pulsatile tinnitus). By contrast, interventions for intracranial atherosclerosis and for other non‑specified indications (including isolated headache) are not recommended and are considered not medically necessary.

    Within the literature citation excerpts shown there are no standalone statements framed as policy-level 'not medically necessary' determinations; those determinations are present in the policy text and exclusions sections rather than in the reference citations.

    Coding and Size/Threshold Key Facts

    CPT codes referenced in cerebrovascular embolization and stent sectionCPT
    61624Transcatheter permanent occlusion or embolization (e.g., for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), including all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention
    61630Balloon angioplasty, intracranial (e.g., atherosclerotic stenosis), percutaneous
    61635Transcatheter placement of intravascular stent(s), intracranial (e.g., atherosclerotic stenosis), including balloon angioplasty if performed
    37238Transcatheter placement of an intravascular stent(s), open or percutaneous; initial vein
    Additional CPT codes (venous angioplasty/stent)CPT
    37239Transcatheter placement of an intravascular stent(s), each additional vein (List separately in addition to code for primary procedure)
    37248Transluminal balloon angioplasty, initial vein (except dialysis circuit), including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same vein
    37249Transluminal balloon angioplasty, each additional vein (except dialysis circuit) (List separately in addition to code for primary procedure)
    inv-14: Asymptomatic saccular aneurysm size
    Asymptomatic saccular aneurysm size≥5 mm
    ContextListed as a standalone medically necessary indication for endovascular treatment when documented in recent clinical history
    Documentation requirementImaging measurement of aneurysm size must be included in prior-authorization request (recent imaging within 6 months)
    inv-15: Asymptomatic saccular aneurysm alternative criterion
    Alternative asymptomatic aneurysm criterion≥3 mm with dysmorphic features or evidence of growth on follow-up imaging
    ContextAcceptable alternative to the ≥5 mm size threshold when dysmorphic features or documented growth are present

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization timing and required materials

    Submit prior-authorization requests at least two weeks before the anticipated date of elective cerebrovascular endovascular procedures and include all required documentation elements for vascular intervention requests.

    • Include proposed procedure and how it matches the clinical need
    • Specify the condition being treated and relevant prior interventions and responses
    • Provide detailed conservative treatment (duration, frequency, response) when applicable
    • Attach recent (within 6 months) diagnostic imaging reports and a recent clinical evaluation documenting symptoms and physical exam
    Prior Authorization

    Prior authorization for cerebrovascular endovascular procedures

    Prior authorization is expected for endovascular intracerebral procedures; requests must include the clinical history, imaging measurements/measurements (e.g., aneurysm size, cSDH thickness, venous stenosis percentage), and evidence that the coverage criteria are met.

    Background

    Endovascular procedures for cerebrovascular pathology encompass embolization, balloon angioplasty, stent placement, and flow diversion. These interventions are used to treat conditions such as arteriovenous malformations (any size), ruptured or symptomatic aneurysms, persistent or recurrent aneurysm filling after prior intervention, highly vascular tumors, chronic subdural hematoma (including consideration of middle meningeal artery embolization for asymptomatic cSDH ≥ 8 mm or symptomatic cSDH), and intracranial venous stenosis when prespecified diagnostic and physiologic criteria are met. Prior authorization is implied for these procedures and requests should include relevant clinical history and recent imaging measurements to demonstrate that the policy criteria are met.

    Definitions and Key Terms

    inv-35: Aneurysm definition
    Aneurysm (definition)Defined as a diameter 1.5× the normal arterial diameter
    Cerebral aneurysm descriptionA bulging, weakened area in the wall of a blood vessel resulting in an abnormal widening or ballooning greater than 50% of the vessel's normal diameter
    Clinical relevanceSize and growth influence rupture risk and treatment considerations
    inv-36: Angioplasty definition
    Angioplasty (definition)A procedure that utilizes a catheter with a balloon that is inflated to enlarge a stenotic area
    Alternate termPTA (percutaneous transluminal angioplasty) is used interchangeably in the document
    Policy Summary
    Payerevicore
    PolicyCerebrovascular Intervention (Endovascular Embolization and Stents)
    Policy CodePolicy CVI.100.A
    Change TypeNo material changes
    Effective DateNov 5, 2026
    Next Review Date
    Key ActionSubmit prior-authorization at least two weeks before elective procedures with required clinical history, recent imaging, and documentation of conservative therapy or prior interventions as applicable.
    SourceLink
    On This Page
    Coverage Criteria for Cerebrovascular Endovascular ProceduresCoding and Size/Threshold Key FactsPrior Authorization, Documentation, and Provider RequirementsBackgroundDefinitions and Key Terms
    Documentation requirementFollow-up imaging demonstrating growth or descriptive imaging report noting dysmorphic features must be provided
    inv-16: Aneurysm size
    Aneurysm size criteria (summary)Medically necessary if ≥5 mm OR ≥3 mm with dysmorphic features or documented growth
    Other indicationsPersistent or recurrent aneurysm filling after prior intervention is also a medically necessary indication regardless of size
    Clinical examplesSymptomatic aneurysm (visual changes or protracted headache) or ruptured aneurysm are independent indications not solely based on size
    inv-17: cSDH thickness
    cSDH imaging thickness threshold≥8 mm (asymptomatic) for consideration of middle meningeal artery embolization
    Other MMAE indicationsSymptomatic cSDH as adjunct to surgical decompression; cSDH with coagulopathy or on antiplatelet therapy; prophylactic embolization after surgical evacuation
    Documentation requirementImaging report with measured cSDH thickness should be included with prior-authorization request
    inv-18: IIH lumbar puncture opening pressure
    IIH lumbar puncture opening pressure threshold>25 cm H2O
    ContextRequired as part of the all-criteria set for endovascular intervention for idiopathic intracranial hypertension (IIH)
    Documentation requirementSpinal tap opening pressure must be documented in the record submitted for prior-authorization
    inv-19: Venous sinus stenosis by imaging
    Imaging stenosis threshold>50% stenosis on MRV, CTV, or venography
    Alternate demonstrationSignificant trans-stenotic pressure gradient during diagnostic catheter venogram (see pressure gradient thresholds)
    ContextRequired documentation element for IIH and pulsatile tinnitus venous stenting consideration
    inv-20: Pressure gradient for IIH
    Pressure gradient threshold for IIH>8 mmHg (measured during diagnostic catheter venogram)
    Pressure gradient threshold for pulsatile tinnitus>4 mmHg (measured during diagnostic catheter venogram)
    UseMeasured gradient is an alternative or adjunct to imaging percent stenosis to document hemodynamically significant venous sinus stenosis
    • Document aneurysm size (e.g., ≥5 mm or ≥3 mm with dysmorphic features or growth) or cSDH thickness (≥8 mm) when applicable
    • For venous procedures, include quantified stenosis (>50%) or measured pressure gradients (>8 mmHg for IIH, >4 mmHg for pulsatile tinnitus)
    • Provide evidence of prior failed therapies when required by the criteria
    Note

    Prior authorization not specified in excerpt

    Some portions of the source are reference citations only and do not specify prior-authorization rules; do not assume additional authorization requirements beyond those explicitly stated in the documentation and prior-auth sections.

    Step Therapy

    Urgent/emergent exceptions to conservative management

    Do not require prior conservative, non‑surgical management when the request documents an urgent or emergent condition (examples: symptomatic carotid stenosis, critical limb ischemia, crescendo TIAs, symptomatic or ruptured aneurysms).

    Step Therapy

    Conservative therapy required before venous stenting

    For IIH and pulsatile tinnitus related to venous sinus stenosis, prior conservative medical therapy must have failed before venous stenting will be considered.

    • Failed medical therapy includes lifestyle changes, diuretics, and acetazolamide therapy
    • Document inability to control symptoms with these measures prior to authorization for stenting
    Note

    No step therapy requirements present in these excerpts

    No formal step therapy program (beyond the condition-specific conservative therapy requirements noted for venous stenting and the urgent/emergent exceptions) is specified in the provided excerpts.

    Documentation Required

    Required documentation (general prior-auth documentation list)

    Prior-authorization requests must include the elements listed for vascular intervention requests: proposed procedure matching clinical need; condition being treated; detailed conservative treatment and response; prior interventions and response; anatomic measurements (aneurysm size, cSDH thickness) when relevant; and recent (within 6 months) diagnostic imaging reports and clinical evaluation.

    • Attach recent (within 6 months) imaging reports (CTA/CTV, MRA/MRV, arteriogram/venogram, duplex, IVUS)
    • Provide recent clinical evaluation documenting symptoms and physical exam findings
    Documentation Required

    IIH venous stenting documentation

    For IIH patients considered for venous stenting, include documentation of papilledema on ocular exam, lumbar puncture opening pressure (>25 cm H2O), prior failed medical therapy, imaging demonstrating venous sinus stenosis (>50% on MRV/CTV/venography) or a significant pressure gradient (>8 mmHg), and the patient’s ability to tolerate dual antiplatelet therapy.

    • Document papilledema on ocular exam
    • Provide lumbar puncture opening pressure (>25 cm H2O)
    • Show failed medical therapy (lifestyle changes, diuretics, acetazolamide)
    • Include imaging demonstrating >50% venous sinus stenosis or pressure gradient >8 mmHg
    • Confirm ability to tolerate ASA and clopidogrel for 1 month
    Documentation Required

    Aneurysm and cSDH documentation (imaging measurements required)

    For aneurysm and chronic subdural hematoma interventions, include imaging measurements and symptom documentation: aneurysm size thresholds (e.g., ≥5 mm or ≥3 mm with dysmorphic features/growth) and cSDH thickness (e.g., ≥8 mm), plus symptom description, prior interventions, and relevant coagulation/anticoagulation status.

    • Report aneurysm size and any evidence of growth or dysmorphic features
    • Provide cSDH measurement on imaging (≥8 mm when applicable)
    • Document symptoms (visual changes, headache), prior treatments, and coagulopathy or anticoagulation status
    Note

    No documentation requirements specified in these reference-list excerpts

    Certain reference-list chunks supply literature citations only and do not specify documentation requirements; do not infer additional documentation obligations from these citations.

    Denial Risk

    Documentation-based denials

    Incomplete prior-authorization documentation—such as missing demonstration that the proposed procedure matches the clinical need, absent documentation of conservative treatment or prior interventions, or lack of recent (within 6 months) imaging/clinical evaluation—may lead to denial of the request.

    • Ensure all required imaging and clinical notes within 6 months are included
    • Include clear documentation of prior conservative therapy and responses when applicable
    • Provide prior intervention details and outcomes when relevant
    Denial Risk

    Intracranial atherosclerosis not indicated

    Requests for endovascular treatment of intracranial atherosclerosis are explicitly stated as not medically necessary and are subject to denial.

    Note

    No authorization or denial criteria present in these literature excerpts

    Some chunks contain literature citations only and do not include authorization or denial criteria; do not treat these citation-only sections as policy requirements.

    Typical useApplied to enlarge stenotic vessels; intracranial angioplasty is generally not recommended for intracranial atherosclerosis except specific indications
    inv-37: Cerebral aneurysm term
    Cerebral aneurysm (term)A bulging, weakened area in the wall of a blood vessel resulting in an abnormal widening or ballooning greater than 50% of the vessel's normal diameter
    CausesMay be congenital, hereditary, or secondary to other medical conditions or injury
    Risk factorsSize increase over time, family history, and prior SAH increase risk of rupture
    inv-38: Chronic subdural hematoma (cSDH)
    Chronic subdural hematoma (cSDH)A collection of subdural blood products typically in elderly patients that can be symptomatic or asymptomatic and is managed with surgical drainage, MMA embolization, or combinations thereof
    Treatment optionsSurgical drainage, middle meningeal artery embolization (MMAE), or both depending on clinical scenario
    Indications for MMAEAsymptomatic cSDH ≥8 mm; symptomatic cSDH adjunct to surgery; cSDH with coagulopathy or on antiplatelet therapy; prophylactic post-evacuation embolization
    inv-39: Selected literature citations
    Systematic review — MMAEOmura Y. & Ishiguro T. (2023). Middle meningeal artery embolization for chronic subdural hematoma: a systematic review
    Venous sinus stenting literaturePatsalides et al. (2019, 2021) and Shields et al. (2019) report outcomes for venous sinus stenting in IIH and pulsatile tinnitus
    Recent meta-analyses and reviewsMultiple 2023–2026 publications summarize MMAE outcomes and long-term stenting results (see references listed)